ASC 41 clinical trials
Also written ASC41.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses ASC 41 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ASC41
- 3
Studies by the year they started
5 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2020 | 3 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Gannex Pharma Co., Ltd. (4) · Ascletis Pharmaceuticals Co., Ltd. (1)
Studies
Open first, then newest update. How each study uses ASC 41 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese SubjectsCompletedPhase 1Gannex Pharma Co., Ltd.NCT04686994Written as ASC 41
- Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy VolunteersCompletedPhase 1Gannex Pharma Co., Ltd.NCT04692025Written as ASC41 tablet
- DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.CompletedPhase 1Gannex Pharma Co., Ltd.NCT04845646Written as ASC41
- Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASHWithdrawnPhase 2Gannex Pharma Co., Ltd.NCT05118360Written as ASC41 2 mg
- A Study of the Relative Bioavailability of ASC41 in Healthy SubjectsCompletedPhase 1Ascletis Pharmaceuticals Co., Ltd.NCT04527250Written as ASC41